“On Friday 1st June 2018, Merck/Pfizer announced that the current BAVENCIO (avelumab) metastatic Merkel cell carcinoma access program in Australia will be closed. Any patient request already approved on the access program was grandfathered on Friday, 1st June, and will continue to receive BAVENCIO stock free of charge until unacceptable toxicity, progression or death.”
Hi, this is a comment.
To get started with moderating, editing, and deleting comments, please visit the Comments screen in the dashboard.
Commenter avatars come from Gravatar.